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Placental malaria (PM) is a major cause of fetal
growth restriction, yet the underlying mechanism is
unclear. Complement C5a and C5a receptor levels
are increased with PM. C5a is implicated in fetal
growth restriction in non-infection-based animal
models. In a case-control study of 492 pregnant
Malawian women, we find that elevated C5a levels
are associated with an increased risk of delivering
a small-for-gestational-age infant. C5a was signifi-
cantly increased in PM andwas negatively correlated
with the angiogenic factor angiopoietin-1 and posi-
tively correlated with angiopoietin-2, soluble endo-
glin, and vascular endothelial growth factor. Genetic
or pharmacological blockade of C5a or its receptor in
a mouse model of PM resulted in greater fetoplacen-
tal vessel development, reduced placental vascular
resistance, and improved fetal growth and survival.
These data suggest that C5a drives fetal growth
restriction in PM through dysregulation of angiogenic
factors essential for placental vascular remodeling
resulting in placental vascular insufficiency.
INTRODUCTION
Over 125 million pregnant women are at risk of malaria infection
every year (Dellicour et al., 2010). A Plasmodium falciparum
infection in pregnancy doubles the risk of delivering a child that
is low birth weight (LBW, <2500 g) (Desai et al., 2007). Malaria-
related LBW is responsible for up to 200,000 infant deaths
each year (Guyatt and Snow, 2001). Fetal growth restrictionCell Host &resulting in small-for-gestational-age (SGA) infants accounts
for approximately half of LBW outcomes associated with
placental malaria (PM); the other half results from preterm
delivery (Steketee et al., 2001; Umbers et al., 2011a). Sequestra-
tion of infected erythrocytes and accumulation of mononuclear
cells in the placental intervillous space are histopathological hall-
marks of PM associated with LBW. Chemokines that promote
monocyte infiltration and inflammatory cytokines secreted by
activated macrophages have been associated with malaria-
related LBW (Umbers et al., 2011a). However, the precise
mechanism by which parasite accumulation and placental
inflammation result in fetal growth restriction, preterm delivery
and LBW remains poorly understood.
The complement system is a central component of innate
host defense and is activated in malaria-infected individuals
(Silver et al., 2010a). Multiple complement activation pathways
converge upon cleavage of component C5 to C5a, which has
recognized roles in induction of inflammation and initiation of
acquired immune response (Guo and Ward, 2005). Levels of
maternal plasma C5a and placental messenger RNA (mRNA)
encoding the C5a receptor, C5aR, are increased with PM
infection (Conroy et al., 2009; Muehlenbachs et al., 2007)
but have not been associated with adverse outcomes in human
malaria infection. C5a has been shown to influence angiogen-
esis (Langer et al., 2010), is increased in women with
preeclampsia (Soto et al., 2010), and has been implicated
as a mediator of poor fetal outcomes in non-infection-based
animal models of fetal loss and growth restriction (Girardi
et al., 2006). Based on these observations, we hypothesized
that C5a might cause fetal growth restriction associated with
PM by creating an imbalance in the angiogenic factors required
for normal placental vascular development and fetal growth
(Dunk et al., 2000; Geva et al., 2002; Gougos et al., 1992;
Venkatesha et al., 2006).Microbe 13, 215–226, February 13, 2013 ª2013 Elsevier Inc. 215
Figure 1. Description of Study Population
(A) Flow chart of samples included as cases (women who were placental malaria positive for Plasmodium falciparum parasites by placental blood smear) or
controls (negative for malaria parasites by placental and peripheral blood smear).
(B) Breakdown of birth outcomes as low birth weight (<2,500 g), preterm (<37 weeks gestation), or small for gestational age (less than tenth percentile for growth).
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Placental Malaria Infection Is Associatedwith Poor Birth
Outcomes
Between 2001 and 2006, we enrolled 606 women who delivered
live, singleton infants at Queen Elizabeth Central Hospital,
Blantyre, Malawi into a case-control study. Cases were defined
by the presence of P. falciparum asexual parasites in the
placental blood, as assessed by smear microscopy. Of the
women enrolled, 492 had live birth outcomes, placental histolog-
ical examination, and available plasma samples and were216 Cell Host & Microbe 13, 215–226, February 13, 2013 ª2013 Elseeligible for the study (Figure 1). The majority (n = 305) of women
were primigravidae. Adverse birth outcomes included LBW,
preterm delivery (<37 weeks of gestation), and fetal growth
restriction, defined as SGA (less than tenth percentile for growth
in sub-Saharan African populations [Landis et al., 2009])
(Figure 1).
Consistent with previous reports (Ismail et al., 2000; Rogerson
et al., 2003), women with placental parasitemia were more likely
to be febrile and anemic and have histopathological evidence of
placental inflammation (Table 1 and Table S1 available online).
PM was associated with increased risk of LBW (adjusted oddsvier Inc.
Table 1. Characteristics Associated with Placental Malaria and Small-for-Gestational-Age Infants in Primigravidae
Placental Malaria Statusa Fetal Growth Statusb
Positive (n = 92) Negative (n = 213) p SGA (n = 94) AGA (n = 208) p
Demographic
Age (years) 18 (17–20) 19 (18–20) 0.038 18 (17–20) 19 (18–20) 0.127
Height (cm) 154 (150–157) 154 (150–158) 0.646 153 (149–158) 154 (150–158) 0.283
Fetal sex (% female) 60.9 47.1 0.028 58.5 48.8 0.118
Weight of baby (g) 2,700 (2,500–3,000) 2,900 (2,600–3,200) 0.001 2,500 (2,288–2,700) 3,025 (2,800–3,300) <0.001
Clinical
Hemoglobin (g/dl) 10.9 (9.6–12.0) 12.5 (11.0–13.7) <0.001 11.4 (10.0–13.0) 12.2 (10.7–13.5) 0.025
Temperature (C) 37.0 (36.2–37.4) 36.2 (36.0–36.6) <0.001 36.5 (36.0–37.0) 36.4 (36.0–37.0) 0.336
Blood pressure > 140/90 (%) 2.2 2.8 1.000 4.3 1.9 0.262
Febrile symptomsc 46.7 5.6 <0.001 20.2 16.3 0.971
Histologic Findings
Monocyte count 30 (12–47) 4 (0–15) <0.001 11 (0–30) 9 (0–22) 0.458
Monocyte pigment scored 2 (1–3) 0 (0–0) <0.001 0 (0–2) 0 (0–1) 0.092
Fibrin pigment scored 3 (1–4) 0 (0–2) <0.001 1 (0–3) 1 (0–3) 0.152
Biomarkers
C5a (ng/ml) 85.7 (64.5–111.3) 71.3 (52.0–87.3) <0.001 78.5 (57.2–106.4) 72.5 (55.2–93.6) 0.059
C3a (mg/ml)e 3.3 (2.3–5.5) 3.8 (2.5–6.5) 0.076 3.8 (2.7–5.4) 3.7 (2.4–6.3) 0.701
Angiopoietin-1 (ng/ml) 28.2 (17.4–49.4) 36.6 (22.2–55.7) 0.006 28.7 (19.1–49.9) 36.1 (20.3–54.9) 0.043
Angiopoietin-2 (ng/ml) 15.2 (8.3–45.6) 11.8 (6.5–31.2) 0.039 15.2 (7.9–41.7) 11.6 (6.4–31.8) 0.048
sTie-2 (ng/ml) 38.1 (30.8–45.6) 35.7 (29.5–42.4) 0.167 36.7 (28.7–44.8) 36.0 (30.3–43.0) 0.827
sEndoglin (ng/ml) 64.5 (36.2–122.2) 47.2 (32.2–85.6) 0.057 67.6 (35.9–119.5) 47.1 (32.1–86.7) 0.027
sFlt-1 (ng/ml) 144.2 (46.3–244.4) 115.3 (40.8–213.8) 0.045 149.1 (54.6–247.8) 113.3 (39.0–212.6) 0.044
VEGF (pg/ml) 82.5 (37.8–181.8) 94.0 (43.5–239.5) 0.277 114.5 (47.5–391.8) 86.5 (38.5–190.3) 0.076
Biomarkers measured by ELISA in placental plasma collected at delivery. Values represented as median (interquartile range). See also Table S1.
aDefined as a positive placental smear.
bFetal growth assessed with a nomogram generated for sub-Saharan populations (Landis et al., 2009). Small for gestational age (SGA) is defined as
birth weight for gestational age less than the tenth percentile. AGA, appropriate for gestational age (Landis et al., 2009).
cAny one of the following: self-reported fever, headache, or chills within the week prior to delivery.
dScore 0–4: 0, none; 1, little; 2, some; 3, moderate; 4, large amounts in every field at 403 objective as assessed by a single observer.
ePM+, n = 81; PM–, n = 174; SGA, n = 81; AGA, n = 171.
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after adjustment for age and gravidity. PM was associated with
increased risk of SGA rather than preterm delivery (Table S2).
Thirty-six percent of mothers with PM at delivery had infants
SGA, while 27% of mothers of appropriate-for-gestational age
(AGA) infants had PM (p = 0.051). Primigravidae with PM had
a median 200 g reduction in birth weight as compared to primi-
gravidae without PM (p = 0.001).
Elevated C5a Levels Are Associated with Fetal Growth
Restriction
We measured and categorized maternal C5a levels as elevated
(>100 ng/ml) or normal (%100 ng/ml) and compared them to birth
outcome (Figures 2A and 2B). A cutoff of 100 ng/ml (10 nM)was
used because above this concentration, C5a can synergistically
induce inflammation, cause monocyte release of the antiangio-
genic factor soluble Fms-like tyrosine kinase-1 (sFlt-1) in the
presence of parasite factors (Conroy et al., 2009), and alter coag-
ulation and white blood cell function (Ward, 2004). Elevated
levels of C5a in the peripheral or placental bloodwere associated
with increased risk of delivering a LBW infant after adjustment forCell Host &maternal and gestational age, gravidity, and PM (aOR [95% CI]:
peripheral, 2.7 [1.1–7.0], p = 0.036; placental, 2.1 [0.91–4.6],
p = 0.081). Elevated C5a levels were associated with SGA status
(aOR [95%CI]: peripheral, 2.4 [1.3–4.4], p = 0.003; placental, 1.7
[1.04–2.8], p = 0.035) more so than preterm delivery (aOR [95%
CI]: peripheral, 0.9 (0.4–1.9), p = 0.696; placental, 0.4 [0.2–0.9],
p = 0.033).
C5a and Angiogenic Factors Are Altered in Placental
Malaria
With the same cutoff of 100 ng/ml, C5a was elevated in both the
peripheral and placental blood of women who were positive for
P. falciparum malaria by placental blood smear microscopy
(odds ratio [95% CI]: peripheral, 1.9 [1.1–3.4], p = 0.023;
placental, 3.0 [1.9–4.8], p < 0.001; by Pearson chi-square anal-
ysis) (Figures 2C and 2D).
Focusing at the site of infection, we also found the median
placental levels of C5a to be higher in both primigravidae (p <
0.001; Table 1) and multigravidae (p = 0.002; Table S1) with
PM than in those without. We investigated placental levels of
angiogenic factors important in forming and remodeling theMicrobe 13, 215–226, February 13, 2013 ª2013 Elsevier Inc. 217
Figure 2. Elevated C5a Levels Are Observed
in a Higher Proportion of Women with Fetal
Growth Restriction and Placental Malaria
We measured and categorized C5a levels in
peripheral and placental blood as elevated
(>100 ng/ml) or not elevated (%100 ng/ml) and
compared them to fetal growth status and
placental malaria status at delivery. The percent-
ages of adverse outcomes (SGA and placental
malaria) are indicated on the graphs.
(A and B) Elevated C5a levels in peripheral or
placental plasma were associated with a higher
proportion of deliveries of SGA infants versus AGA
infants (peripheral, p = 0.003; placental, p = 0.007
Pearson chi-square test).
(C and D) A higher proportion of women with
placental malaria (PM+) than uninfected women
(PM–) had elevated C5a levels in peripheral or
placental plasma (peripheral, p = 0.023; placental,
p < 0.001; Pearson chi-square test).
See also Table S2.
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poietin-1 (Ang-1), Ang-2, vascular endothelial growth factor
(VEGF), sFlt-1, and soluble endoglin (sEng) (Dunk et al., 2000;
Geva et al., 2002; Gougos et al., 1992; Venkatesha et al.,
2006). Median Ang-1 levels in both primigravid (p = 0.006; Table
1) and multigravid (p = 0.024; Table S1) women with PM were
lower than in control women without PM. Conversely, there
were higher median levels of Ang-2, sFlt-1, and sEng in primigra-
vidae (Ang-2, p = 0.039; sFlt-1, p = 0.045; sEng, p = 0.057) and
multigravidae (Ang-2, p = 0.011; sFlt-1, p = 0.020; sEng, p =
0.001) with PM than in controls.
In primigravidae, C5a levels were negatively correlated with
Ang-1 (Spearman’s rho, 0.27; p < 0.001) and positively corre-
lated with Ang-2 (0.38; p < 0.001), sEng (0.46; p < 0.001),
VEGF (0.32; p < 0.001), and sFlt-1 (0.42; p < 0.001). Multigravidae
showed the same relationships between C5a and angiogenic
factors, except for sFlt-1, where the correlation was weaker
(Spearman’s rho, 0.19; p = 0.009).
Dysregulated Placental Angiogenic Factors Are
Associated with Fetal Growth Restriction
Ang-1 levels were lower in women who delivered SGA
infants than those who delivered AGA infants (p = 0.043). Addi-
tionally, Ang-2, sEng, and sFlt-1 were significantly increased
in women who delivered SGA infants compared to those who
delivered AGA infants (Tables 1 and S1). A trend toward
increased VEGF was observed in primigravidae and multi-
gravidae delivering SGA infants (p = 0.076 and p = 0.073,
respectively).218 Cell Host & Microbe 13, 215–226, February 13, 2013 ª2013 Elsevier Inc.Structural Equation Modeling
Supports a Role for C5a in Initiating
Dysregulated Angiogenesis and
Fetal Growth Restriction in
Placental Malaria
We applied structural equation modeling
to test our hypothesis that C5a mediates
fetal growth restriction by altering the
expression of angiogenic factors in theplacenta within a multivariate framework (Figure 3). We gener-
ated our structural equation model using a current under-
standing of factors involved in PM pathogenesis (Rogerson
et al., 2007) including factors known to affect fetal size (e.g.,
maternal height and fetal sex). Through a process of trimming,
we subsequently removed variables that were insignificant
(p > 0.05) to generate a final model where each path represents
a significant relationship after adjustment for all other covariates
(p < 0.05). We then assessed how well the model as a whole
corresponds to the data using standard measures of fit. We
generated a latent variable ‘‘mononuclear cell infiltrates’’
composed of mononuclear cell counts and semiquantitative
assessments of monocyte and fibrin pigment that indicate
the chronicity of infection (Ismail et al., 2000; Rogerson et al.,
2003) (Figure 3A). In this model, mononuclear cell infiltration is
inversely related to maternal hemoglobin levels, and maternal
hemoglobin level is a major determinant of preterm delivery
and fetal growth restriction. We also constructed the latent con-
cept ‘‘dysregulated angiogenesis’’ to reflect several measured
variables (proangiogenic factor Ang-2 and antiangiogenic
factors sFlt-1 and sEng) that change with similar patterns
(Figure 3B).
Supporting the validity of the model and in agreement with an
accepted understanding of PM, this model indicates that our
case-control data fit a sequence of events whereby malaria
parasites initially sequester in the placenta and lead to the accu-
mulation of monocytes (Figure 3C). Moreover a unique compo-
nent of our model is the axis focusing on C5a and fetal growth
restriction (Figure 3C). Our human data fit a model in which
Figure 3. Structural Equation Model for Complement Activation, Dysregulated Placental Angiogenesis, and Birth Outcomes in Primigravid
Women with Placental Malaria
Positive associations are indicated by black lines and inverse associations by red lines; lines represent significant relationships (p < 0.05) after correcting for all
other covariates. Standardized regression coefficients (range, 1.0 to +1.0) of factors associated with placental malaria infection and poor birth outcomes.
(A) The latent variable ‘‘mononuclear cell infiltrates’’ is comprised of the mononuclear cell count, and a semiquantitative score of pigmented mononuclear cells
and fibrin pigment (0, none, to 4, large amounts of pigment in every field at 403 objective), as assessed by histology.
(B) The latent variable ‘‘dysregulated angiogenesis’’ is comprised of measures of proangiogenic factor Ang-2, antiangiogenic factor sFlt-1 (which sequesters
VEGF), and antiangiogenic factor sEng.
(C) A structural equation model was generated positing howmalaria may contribute to adverse birth outcomes through complement activation and dysregulated
angiogenesis. This model includes fetal sex, maternal height, and the latent variable ‘‘febrile symptoms,’’ composed of self-reported fever, headache, or chills
1 week prior to delivery (omitted here for clarity). The overall fit of the model was good (chi-square = 381.2; df = 282; p < 0.001; root-mean-square error of
approximation [rmsea] = 0.027 [90% CI: 0.019–0.033]).
See also Figure S1 and Table S3.
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ation of C5a, and the resultant increase in C5a initiates dysregu-
lated angiogenic responses including increases in Ang-2, sFlt-1,
and sEng (Figure 3C). In this model, C5a also modulates angio-Cell Host &genesis by reducing Ang-1 levels and increasing VEGF.
Together, the dysregulated angiogenic factors promote fetal
growth restriction and SGA infants.We show results for primigra-
vidae since the greatest burden of LBWoccurs in this population;Microbe 13, 215–226, February 13, 2013 ª2013 Elsevier Inc. 219
Figure 4. C5a-C5aR Mediates Fetal Growth
Restriction and Fetal Loss in aMouseModel
of Placental Malaria
(A) C5aR mRNA transcript levels increase in G19
placentas associated with viable fetuses of wild-
type (C5aR+/+) mice infected with P. berghei at
G13. Box plots show the median, interquartile
range with whiskers denoting the maximum and
minimum values. **p < 0.01.
(B) Percent of viable fetuses. Viability of fetuses
was increased in C5aR-deficient (C5aR/) mice
infected with P. berghei compared to infected
C5aR+/+ mice. *p = 0.021.
(C) C5aR deficiency (C5aR/) and antibody-
mediated blockade of C5aR but not C5L2 reduced the fetal growth restriction observed in viable fetuses of wild-type (C5aR+/+) mice infected with P. berghei.
Viable fetuses were weighed at G19, 6 days after G13 pregnant mice received an injection of medium alone (UI) or 106 P. berghei infected-erythrocytes in medium
(infected). Bars represent groupmedians, and dots represent individual viable fetuses. Administration of C5aR (anti-C5aR) or C5a antiserum (anti-C5a) to infected
pregnant C5aR+/+mice increased G19 fetal weight compared to preimmune control serum (Ctrl), whereas blocking the alternative C5a receptor, C5L2, with anti-
C5L2 antiserum did not provide any further protection against fetal growth restriction over that afforded by C5aR deficiency alone. **p < 0.01; ***p < 0.0001 by
Bonferroni post hoc test of one-way ANOVA. n = 3–15 litters per group.
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the same C5a-mediated processes occur in PM in all gravidities
(Figure S1 and Table S3). These data are not consistent with
a model in which C5a initiates placental monocyte recruitment
(p > 0.05). Rather, when taken together, these human data
support a role for C5a as a cause of poor fetal growth through
altered angiogenesis.
Interruption of C5a-C5aR Signaling Improves Fetal
Outcomes
To provide direct experimental evidence of the central role of
C5a inmalaria-induced fetal growth restriction, we used amouse
model that recapitulates characteristics of PM in primigravidae
(Neres et al., 2008). In brief, these include binding of parasitized
erythrocytes to placental vascular walls, placental accumulation
of monocytes, and decreased fetal viability and growth (Neres
et al., 2008). Infection of naturally mated pregnant mice at
gestational day 13 (G13; beginning of the third trimester of
a normal 20 day mouse gestation) with the rodent malaria
parasite, Plasmodium berghei ANKA, led to fetal growth restric-
tion asmeasured by a significant reduction in theweight of viable
fetuses at G19 (mean [95%CI]: uninfected, 1,082mg [1,042 mg–
1,090 mg]; infected, 776 mg [744 mg–808 mg]; p < 0.0001).
P. berghei infection of pregnant mice was associated with an
increase in placental levels of mRNA encoding the C5a receptor
(C5aR, CD88) (Figure 4A). Genetic deficiency of C5aR (C5aR/)
significantly increases fetal growth in the presence of PM: the
mean weight of fetuses from infected C5aR/ mice was signif-
icantly higher than that of fetuses from infected wild-type
(C5aR+/+) mice (mean [95% CI]: C5aR+/+, 776 mg [744 mg–
808 mg]; C5aR/, 913 mg [843 mg–982 mg]; p = 0.0013).
Peripheral parasitemia was comparable in both genotypes and
with all treatments (data not shown). Additionally, C5aR defi-
ciency increased fetal viability at G19 by 50% (p = 0.021;
Figure 4B).
A significant improvement in fetal growth was also achieved
by blocking C5a-C5aR signaling with antiserum to C5a or
C5aR during malaria infection in wild-type (C5aR+/+) mice (Fig-
ure 4C). In contrast, blocking the alternative C5a receptor,
C5L2 (Bamberg et al., 2010; Chen et al., 2007; Ward, 2009),220 Cell Host & Microbe 13, 215–226, February 13, 2013 ª2013 Elsedid not further improve fetal weight in infected C5aR/ mice
(Figure 4C).
Placental Angiogenic Factor Transcription Is Altered
with Malaria Infection
Using quantitative real-time PCR, we observed a change in
placental angiopoietin transcript levels in favor of Ang-2 in in-
fected murine placentas (Figure 5A): Ang-2 increased (infection:
p = 0.026 [two-way ANOVA]) and Ang-1 decreased (infection:
p = 0.0004 [two-way ANOVA]) with infection. This increase in
Ang-2/Ang-1 was observed regardless of C5aR genotype.
Placental VEGFmRNA expression was increased with malaria
(p = 0.031 [two-way ANOVA]; Figure 5B), but this increase was
independent of genotype. In C5aR+/+ mice, the increase was
accompanied by a proportional increase in sFlt-1 transcription,
which resulted in a consistent VEGF/sFlt-1 ratio. In contrast,
C5aR deficiency resulted in a significant increase in placental
VEGF/sFlt-1 ratio with infection, mainly due to a decrease in
sFlt-1 transcription in the absence of C5a-C5aR signaling
(p = 0.027 [Mann Whitney]; Figure 5B). The increase in pro-
angiogenic VEGF to antiangiogenic sFlt-1 favors a placental
environment permissive to placental angiogenesis and vascular
remodeling (Maynard et al., 2003).
Placental Malaria-Induced C5a-C5aR Signaling Alters
Placental Vascular Development
To examine the effect of malaria-induced changes in comple-
ment activation and angiogenic factors on placental vessel
structure, we imaged contrast-agent-perfused G18 fetoplacen-
tal arterial vasculature with microcomputed tomography (mi-
croCT) (Rennie et al., 2011). At G18, all fetuses were viable,
and those from infected mice were the same weight as those
from uninfected mice (Table S4). Therefore, any changes in the
placental vasculature we observed at this point precede the
poor fetal outcomes observed at G19.
Three dimensional (3D) analysis of the fetoplacental arterial
vasculature revealed a significant increase in placental vessels
in the presence of PM (p = 0.017), particularly in vessels of 50–
100 mm diameter. Notably, significantly greater placental vessel
development occurred with C5aR deficiency as compared tovier Inc.
Figure 5. Placental Angiogenic Factor mRNA Expression Is Altered with Infection and C5aR Genotype
(A) Infected placentas associated with viable fetuses had increased expression of mRNA encoding Ang-2/Ang-1 regardless of C5aR genotype corresponding to
an increase in Ang-2 (infection: p = 0.026, two-way ANOVA) and decrease in Ang-1 (infection: p = 0.0004).
(B) The ratio of VEGF/sFlt-1 was unchanged in infected placentas associatedwith viableC5aR+/+ fetuses but significantly elevated in infectedC5aR/ placentas.
This appears to be the result of a decrease in sFlt-1 mRNA copy numbers in infected C5aR/ placentas (p = 0.022 compared to infected C5aR+/+ placentas).
Overall, VEGF mRNA was increased in infection (p = 0.031, two-way ANOVA), but the increase was independent of genotype.
Bars represent group medians and dots represent individual viable fetuses for ratios. Box plots show the median, interquartile range with whiskers denoting the
maximum and minimum values. *p < 0.05; ***p < 0.0001. n = 10 placentas from five to eight litters per group.
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S1). The increased placental vascular development was charac-
terized by an increase in the total length, surface area, volume,
and span of the fetoplacental vasculature infected C5aR/
placentas as compared to infectedC5aR+/+ placentas (Figure 6B
and Table S4). Functionally, PM led to markedly increased
placental arterial vascular resistance inC5aR+/+mice. This effect
was completely abrogated with C5aR deficiency (Figure 6C).
In summary, these data support our hypothesis that C5a-
C5aR signaling impairs vascular remodeling necessary to com-
pensate for the placental insult induced by the presence of
parasitized erythrocytes and/or inflammatory mediators, leading
to increased placental vascular resistance.
DISCUSSION
The biological processes that differentiate healthy from patho-
logical pregnancy outcomes remain poorly defined. Our findingsCell Host &provide evidence in humans of a direct connection between
innate responses to infection (C5 activation) and altered
placental vascular remodeling that result in poor birth outcomes.
A critical role for C5a in the pathogenesis of PM and LBW is sup-
ported by several observations. First, we show that C5a levels
are increased in women of all gravidities with PM. Second,
high systemic and placental C5a levels are associated with
increased odds of delivering a SGA infant. Third, structural equa-
tion modeling of data from our case-control study supports
a model in which C5a initiates angiogenic dysregulation and fetal
growth restriction. Finally, using a mouse model of PM, we
provide direct experimental evidence that C5a could achieve
its effect on fetal viability and growth through its effects on
placental vascular development.
Remodeling of uterine and placental vasculature is essential
for normal placental function and fetal growth. Placental vascular
development and remodeling are controlled primarily through
the highly regulated actions of angiogenic factors from theMicrobe 13, 215–226, February 13, 2013 ª2013 Elsevier Inc. 221
Figure 6. C5a-C5aR Mediates Placental Insufficiency in a Mouse Model of Placental Malaria
(A) Representative microCT imaging of G18 fetoplacental arterial vasculature from infected C5aR+/+ or C5aR/ mice color-coded by vessel diameter.
(B) InfectedC5aR/ placentas had increased cumulative vessel numbers when compared to either uninfectedC5aR/ placentas (p < 0.001) or infectedC5aR+/+
placentas (p < 0.001; post hoc test of repeated-measures ANOVA). Plot depicts the number of fetoplacental arterial vessels larger than the threshold diameter.
Lines represent the mean and SEM.
(C) This increase in vessel number in C5aR/ placentas allowed for the arterial resistance to remain low with infection (p < 0.0001 by Bonferroni post hoc test of
one-way ANOVA; infected C5aR+/+ versus C5aR/). n = 5–8 placentas from three to four litters per group. Box plot shows the median, interquartile range with
whiskers denoting the maximum and minimum values.
See also Table S4 and Movie S1.
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Placental Malaria, Complement, and AngiogenesisVEGF and angiopoietin families (Geva et al., 2002). Ang-1 has
a major role in the stabilization and maturation of newly formed
vessels, whereas Ang-2 provides the destabilizing effect neces-
sary to initiate vascular remodeling (Jeansson et al., 2011;
Yancopoulos et al., 2000). VEGF is necessary for early vessel
formation, whereas its soluble receptor, sFlt-1, can inhibit angio-
genesis through its ability to bind VEGF and placental growth
factor (Levine et al., 2006b). VEGF, which is both proinflamma-
tory and proangiogenic, requires tight regulation during fetal
development since either high or low levels result in embryonic
lethality (Carmeliet et al., 1996; Hiratsuka et al., 1998; Miquerol
et al., 2000). Perturbation of these angiogenic factors have also
been reported in preeclampsia and fetal growth restriction asso-
ciated with inadequate placental vascularization (Kaufmann
et al., 2003).
PM is believed to lead to placental insufficiency, a progressive
deterioration in placental function and inability to sustain fetal
growth, resulting in LBW infants at increased risk of perinatal
mortality (Umbers et al., 2011a). Previous reports are consistent
with the hypothesis that PM may influence angiogenesis and
vascular development. Histological and ultrasound studies of
PM suggest that malaria infection alters the placental vascular
structure (Arbeille et al., 2003; Dorman et al., 2002; Leke et al.,
2002). Altered levels of angiopoietins, sEng, VEGF, sFlt-1, or
C5a have recently been shown in several populations of African
women with PM at delivery (Conroy et al., 2009; Silver et al.,
2011; Silver et al., 2010b). However, it has been unclear whether
these changes are a cause or consequence of fetal growth
restriction and, if the former, where they are positioned in
the sequence of events leading to LBW. We show how alter-222 Cell Host & Microbe 13, 215–226, February 13, 2013 ª2013 Elseations in a comprehensive panel of different angiogenic
factors were related to fetal growth restriction in PM. Future
studies will need to address how changes in these proteins early
in pregnancy lead to functional and structural changes in the
placenta.
Structural equation modeling provides an opportunity to
model putative hierarchal relationships in complex data sets
and helps to overcome the limitations of studying mechanisms
localized to the placenta, which cannot be ethically tested
throughout pregnancy. In our case-control study, we observed
a shift in angiopoietin levels favoring the proangiogenic Ang-2,
supporting the premise that malaria induces angiogenic remod-
eling of the placenta. At the same time, C5a-C5aR signaling can
inhibit angiogenesis by inducing sFlt-1 (Girardi et al., 2006;
Langer et al., 2010). In this study, increased protein levels of anti-
angiogenic factor sFlt-1 correlated with elevations in C5a in all
gravidae with PM and in primigravidae who delivered SGA
infants. High sFlt-1 levels may result in less free VEGF available
to stimulate placental vessel growth (McKeeman et al., 2004).
Application of structural equation modeling to this case-control
data set confirmed the relationship of known risk factors for
LBW, including maternal anemia, and provided a putative
sequence of events linking C5a and the observed changes in
placental angiogenic factors. All data supporting the model
were collected at delivery, and therefore our ability to model
the effect of malaria on angiogenesis throughout pregnancy is
limited; but based on the best fit to these data, the model
provides evidence for where in the pathological pathway from
malaria infection to LBW each factor is most accurately situated.
Our data fit a model in which C5 activation is an initiating eventvier Inc.
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VEGF, and sFlt-1, which then contribute to SGA and LBW
infants. The model further illustrates that placental mononuclear
cells might be directly cleaving C5 or amplifying C5a production
in PM (Huber-Lang et al., 2006), although other factors, which we
were unable to measure in this study (e.g., immune complexes),
might also contribute to complement activation.
Direct experimental evidence to support these observations
was obtained in a murine model of PM. Wild-type mice with
PM had reduced fetal viability and lower fetal weight compared
to uninfected mice. Functionally, these mice had increased
placental resistance despite increased vascular remodeling
observed with microCT of placentas. Ablation of C5a-C5aR
signaling in this model was characterized by an increase in the
placental ratio of VEGF/sFlt-1 mRNA levels and enabled
compensatory vascular remodeling and improved fetal growth
and survival. Continued production of C5a in wild-type mice
was associated with decreased vascular development, mainly
though the production of the antiangiogenic protein sFlt-1.
These findings are in agreement with our previous report that
sFlt-1 secretion in response to in vitro stimulation with malaria
bioactive products is decreased when C5a-C5aR signaling is
blocked by antibody treatment (Conroy et al., 2009) and with
the association of sFlt-1 levels with predicting adverse birth
outcomes in PM and preeclampsia (Levine et al., 2006a; Mueh-
lenbachs et al., 2008). Moreover, we show upregulation of C5aR
in infected placentas, similar to findings in PM in Tanzanian
women (Muehlenbachs et al., 2007). While blocking C5a-C5aR
interactions improved fetal growth, blockade of C5L2 did not
improve fetal outcome beyond that ofC5aR deficiency, suggest-
ing that this alternative C5a receptor (Bamberg et al., 2010;
Ward, 2009) is not involved in mediating pathogenic responses
in the mouse model of PM. Taken together, these data suggest
a mechanism of pathogenesis whereby there is compensatory
vascular remodeling in response to increased vascular resis-
tance in PM, which is associated with increases in Ang-2 and
decreases in Ang-1, favoring angiogenesis. Moreover, increased
C5a-C5aR signaling in PM induces sFlt-1 that impairs the
vascular remodeling required to compensate for increases in
placental vascular resistance. When C5a-C5aR signaling is pre-
vented by genetic or pharmacological strategies, there is
enhanced vascular development and a sufficient compensatory
response to decrease vascular resistance and improve fetal
outcomes.
Although of considerable interest, this model has limitations,
including that the mice are immunologically naive to P. berghei,
which results in a higher peripheral parasitemia than would
be expected in primigravidae in malaria endemic regions. How-
ever, this model provides an opportunity to define a response to
PM that may be anticipated in nonimmune human populations
and, in conjunction with data from semiimmune human popula-
tions, can establish causal relationships and provide mecha-
nistic insights that would be difficult or unethical to acquire in
human studies. Further, while the murine placental structure
does differ from that of humans, our understanding of genetic
regulation of branching morphogenesis and vascularization of
the placenta (Sapin et al., 2001; Watson and Cross, 2005)
and of environmental factor effects (Rennie et al., 2011) have
been rapidly advanced by the use of mice with targetedCell Host &mutations, and this approach holds utility in validating hypoth-
eses originating from analysis of clinical data, as we have
done here.
This study visualizes the effect of infection on placental vascu-
lature using microCT. The vascular structures derived from
the microCT scans enabled the modeling of resistance of the
fetoplacental vasculature to blood flow. This study also demon-
strates a functional role for C5a-C5aR in impaired vascular re-
modeling in the placenta. Despite an increase in vessel numbers
in malaria-infected placentas, there was an increase in vascular
resistance, suggesting that the compensatory vascular remodel-
ing induced by malaria was insufficient in the presence of C5
signaling. C5aR deficiency completely reversed the malaria-
dependent increase in placental vascular resistance. Maternal
vascular resistance is associated with fetal growth restriction
(Ghosh et al., 2006). Peripheral malaria parasitemia after
32 weeks of gestation doubled the risk of abnormal uterine artery
blood flow velocity waveforms, and this was associated with
a doubled risk of low birth weight in a Kenyan population (Dor-
man et al., 2002). That a single signaling pathway could account
for this vascular phenotype induced by malaria is attractive for
the development of therapeutic interventions. These findings
may also have broad implications for other pregnancy complica-
tions associated with immune activation and placental insuffi-
ciency (e.g., preeclampsia), where both C5a and sFlt-1 have
been associated with adverse birth outcomes (Lynch and
Salmon, 2010).
Collectively, our findings suggest that in PM, C5a dysregulates
angiogenic factors, counteracts angiopoietin-mediated com-
pensation for PM and inflammation (Umbers et al., 2011a),
and contributes to fetal growth restriction through functional
placental vascular insufficiency and increased placental resis-
tance to blood flow. In the murine PM model, it is technically
challenging to demonstrate a causal relationship between
altered angiogenesis and poor fetal outcomes, as manipulation
of VEGF signaling or Ang-Tie-2 signaling results in embryonic
lethality (Carmeliet et al., 1996; Miquerol et al., 2000; Sato
et al., 1995). However, population data from Tanzania demon-
strated that a FLT1 variant associated with increased sFlt-1
production was associated with prior pregnancy loss and LBW
in primigravidae (Muehlenbachs et al., 2008). These findings
together with the ones described here support the concept
that altered angiogenesis occurs in malaria and is associated
with poor birth outcomes.
Like other evolutionarily ancient systems, the complement
system has diverse effector functions. Through C5a production,
the complement system can rapidly amplify an inflammatory
response. The association of inflammation with poor birth
outcomes has been well described in PM (Rogerson et al.,
2003; Umbers et al., 2011a). For example, inflammation can
affect the expression of growth regulating hormones (e.g., IGF
and leptin), leading to poor fetal growth (Umbers et al., 2011b).
Our findings do not exclude a contribution of inflammation
in adverse outcomes of PM, but rather suggest that inflammatory
and angiogenic pathways may mediate deleterious outcomes
through a shared component, C5a. We have previously shown
that C5a could amplify inflammatory and antiangiogenic
responses in vitro in the presence of malaria toxin PfGPI (Conroy
et al., 2009). The relative contribution of (and interactionMicrobe 13, 215–226, February 13, 2013 ª2013 Elsevier Inc. 223
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Placental Malaria, Complement, and Angiogenesisbetween) inflammatory and angiogenic proteins will need to be
prospectively assessed.
Our finding that C5a also contributes to increased fetal death
in the murine model of PM is consistent with its defined role in
non-infection-based animal models of fetal loss (Girardi et al.,
2006). We were unable to validate this finding in humans in this
study since only women with live births were enrolled, but given
that malaria has been shown to increase the risk of stillbirth (Wort
et al., 2006; Yatich et al., 2010), future studies should examine
the role of C5a in PM-related stillbirth. Likewise, further examina-
tion of C5a in malaria-associated preterm birth is warranted.
The link we have established between C5a, angiogenic factor
dysregulation, and fetal growth restriction in PM suggests poten-
tial biomarkers to predict women at risk of adverse birth
outcomes, such as LBW, and potential targets for intervention
to prevent these complications.
EXPERIMENTAL PROCEDURES
Participants and Specimens
Between 2001 and 2006, pregnant women delivering a live singleton newborn
at Queen Elizabeth Central Hospital, Blantyre, Malawi were recruited into
a case-control study. Cases were defined by the presence of P. falciparum
asexual parasites in the placental blood, as assessed by smear. For each
case, two age- (±2 years) and gravidity-matched controls negative for malaria
parasites by both peripheral and placental smear were enrolled. The study was
approved by the ethics committee of The College of Medicine, Blantyre,
Malawi, and written informed consent was obtained from all participants.
At delivery, birth weight was recorded, gestational age was assessed (Bal-
lard et al., 1979), and maternal peripheral and placental EDTA plasma samples
were collected and stored at 80C. The following were considered adverse
birth outcomes: low birth weight (< 2,500 g), preterm delivery (<37 weeks of
gestation), and fetal growth restriction, defined as SGA (less than tenth
percentile for growth in sub-Saharan African populations [Landis et al., 2009]).
Biomarker ELISAs
C5a, Ang-1, Ang-2, soluble Tie-2 (sTie-2), sEng, VEGF, and sFlt-1 levels
(DuoSets) and C3a (354113 and purified polyclonal goat IgG) (R&D Systems,
Minneapolis, MN) were measured by ELISA (Conroy et al., 2010). All samples
were tested consecutively, on the first thaw, with the investigator blinded to
group and outcome.
Mouse Model of Placental Malaria
Experiments involving animals were reviewed and approved by the University
Health Network Animal Resource Centre and performed in compliance with
the Canadian Council for Animal Care. Eight- to ten-week-old BALB/c mice
(wild-type [C5aR+/+] or C5aR/) were obtained from Jackson Laboratories
(Bar Harbor, ME). Cryopreserved P. berghei ANKA (MR4; Manassas, VA)
was thawed and passaged through male BALB/c mice. Naturally mated preg-
nant mice were infected on G13 with 106 P. berghei-infected erythrocytes in
RPMI medium via injection into the lateral tail vein. Control (uninfected) preg-
nant mice were injected with the same volume of RPMI medium alone. Para-
sitemia wasmonitored daily by thin blood smear stained with modified Giemsa
stain (Protocol Hema3 Stain Set, Sigma, Oakville, ON). For blocking experi-
ments, polyclonal rabbit antiserum raised against C5aR, polyclonal rabbit anti-
serum raised against C5L2, polyclonal goat antiserum raised against rat C5a
(Riedemann et al., 2002), or preimmune control serum (Sigma) was adminis-
tered in two 250 ml doses, at 2–3 hr prior to malaria infection and 3 days after
infection, via injection into the lateral tail vein.
Pregnant female mice were euthanized by CO2 on G19 (i.e., 6 days after
infection/control injection). Yolk sacs were dissected from uteri, fetuses
were removed and weighed, and placentas were snap frozen and stored at
80C until analyzed. Fetal viability was determined by assessment of pedal
withdrawal reflex. Nonviable fetuses (i.e., lacking the pedal withdrawal reflex)
were considered aborted.224 Cell Host & Microbe 13, 215–226, February 13, 2013 ª2013 ElsePlacental Transcript Analysis
RNA was extracted from snap-frozen mouse placentas after homogenization
in TRIzol (1 ml/100 mg tissue; Invitrogen, Burlington, ON) according to the
manufacturer’s protocol. Extracted RNA (2 mg per sample) was treated with
DNase I (Ambion, Streetsville, ON) and reverse transcribed to complementary
DNA (cDNA) with SuperScript III (Invitrogen) in the presence of oligo (dT)18
primers (Fermentas, Burlington, ON). Residual RNA was degraded with RNase
H (Invitrogen, Burlington, ON). Sample cDNA was amplified in triplicate with
SYBR Green master mix (Roche, Laval, QC) in the presence of 1 mM both
forward and reverse primers in a Light Cycler 480 (Roche). Transcript number
was calculated based on cross-threshold as compared to a standard curve of
mouse genomic DNA included on each plate by Light Cycler 480 software
(Roche), and normalized to geometric average of GAPDH and HPRT expres-
sion levels. See the Supplemental Experimental Procedures for primer
sequences.
Fetoplacental Vasculature Analysis
In preparation for microCT scanning a radio-opaque silicone rubber contrast
agent (Microfil; Flow Technology, Carver, MA) was perfused via the umbilical
artery via methods previously described (Rennie et al., 2011). See the Supple-
mental Experimental Procedures for details of perfusion protocol and how
quantification of vascular measurements was obtained. Vascular resistance
was calculated with standard formulas for resistance in parallel and in series
(Yang et al., 2010) and the viscosity of blood in small vessels (Pries and Se-
comb, 2003). The distribution of pressure and flow in the tree was calculated
assuming (1) Posieuille’s law for flow of fluid through a pipe-like structure, (2)
equal pressure at each terminal vessel, and (3) a diameter dependent blood
viscosity correction affecting small vessels as previously described (Pries
and Secomb, 2003). Analysis was performed on placentas from wild-
type (nuninfected = 7 from four litters; ninfected = 7 from four litters) and C5aR
/
(nuninfected = 5 from three litters; ninfected = 8 from three litters) mice. One data
set (C5aR+/+ uninfected) for which the umbilical vessel was not present due
to the umbilical cord being tied off too close to the chorionic plate during the
perfusion process was eliminated from hemodynamic modeling analyses.
Statistical Analysis
Continuous variableswere analyzed byMann-WhitneyU test. Categorical data
were analyzed by Pearson’s chi-square test or Fisher’s exact test. Adjusted
odds ratios were obtained via logistic regression (SPSS). In order to test our
hypothesis within a multivariate framework, we employed structural equation
modeling (AMOS) to simultaneously examine the relationships between
multiple dependent and independent variables (Calis et al., 2008), as well as
latent concepts and their multiple indicators. Risk factors for adverse
outcomes in pregnancy were included in exploratory models and, through
a process of trimming, were subsequently removed if insignificant (p > 0.05;
e.g., number of antenatal visits, number of antimalarial doses). Inflammatory
cytokines were not measured, so their relative impact on angiogenesis and
birth outcomes was not assessed in this structural equation model. Model
estimates were generated via maximum-likelihood estimation, and fitness
was assessed via the likelihood ratio test statistic (Byrne, 2010), expressed
as chi-square and rmsea, respectively. A low rmsea (<0.05) and a narrow
confidence interval indicate a good fit. Nonstandardized coefficients for the
structural equation model are listed in Table S2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure, four tables, Supplemental
Experimental Procedures, and one movie and can be found with this article
online at http://dx.doi.org/10.1016/j.chom.2013.01.010.
ACKNOWLEDGMENTS
We thank all the women for participating in this study as well as the study team
for their effort. This work was supported by Global Alliance to Prevent Preterm
Birth and Still birth and Grand Challenges in Global Health: Preventing Preterm
Birth Initiative grant number 12003 (K.C.K.); the Canadian Institutes of Health
Research (CIHR) MOP-115160 and 13721 (K.C.K.), Canada Research Chair
(K.C.K.), and Doctoral Research Award (A.L.C.); Genome Canada throughvier Inc.
Cell Host & Microbe
Placental Malaria, Complement, and Angiogenesisthe Ontario Genomics Institute (K.C.K.); and a MITACS Elevate Postdoctoral
Fellowship (K.L.S.). S.J.R. was supported by a Wellcome Trust Senior
Research Fellowship. The funding source had no role in the study design,
data collection, data analysis, data interpretation, or writing of the report.
Received: August 22, 2012
Revised: October 27, 2012
Accepted: December 7, 2012
Published: February 13, 2013
REFERENCES
Arbeille, P., Carles, G., Georgescu, M., Tobal, N., Herault, S., Bousquet, F.,
and Perrotin, F. (2003). Consequences of reduced umbilical and increased
foetal cerebral flow during malaria crisis on foetal behaviour. Parasitology
126, 513–519.
Ballard, J.L., Novak, K.K., and Driver, M. (1979). A simplified score for assess-
ment of fetal maturation of newly born infants. J. Pediatr. 95, 769–774.
Bamberg, C.E., Mackay, C.R., Lee, H., Zahra, D., Jackson, J., Lim, Y.S.,
Whitfeld, P.L., Craig, S., Corsini, E., Lu, B., et al. (2010). The C5a receptor
(C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol.
Chem. 285, 7633–7644.
Byrne, B.M. (2010). Structural Equation Modeling with AMOS: Basic
Concepts, Applications, and Programming, Second Edition (New York:
Routledge).
Calis, J.C., Phiri, K.S., Faragher, E.B., Brabin, B.J., Bates, I., Cuevas, L.E., de
Haan, R.J., Phiri, A.I., Malange, P., Khoka, M., et al. (2008). Severe anemia in
Malawian children. N. Engl. J. Med. 358, 888–899.
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein,
M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996).
Abnormal blood vessel development and lethality in embryos lacking a single
VEGF allele. Nature 380, 435–439.
Chen, N.J., Mirtsos, C., Suh, D., Lu, Y.C., Lin, W.J., McKerlie, C., Lee, T.,
Baribault, H., Tian, H., and Yeh, W.C. (2007). C5L2 is critical for the biological
activities of the anaphylatoxins C5a and C3a. Nature 446, 203–207.
Conroy, A., Serghides, L., Finney, C., Owino, S.O., Kumar, S., Gowda, D.C.,
Liles, W.C., Moore, J.M., and Kain, K.C. (2009). C5a enhances dysregulated
inflammatory and angiogenic responses to malaria in vitro: potential implica-
tions for placental malaria. PLoS ONE 4, e4953.
Conroy, A.L., Phiri, H., Hawkes, M., Glover, S., Mallewa, M., Seydel, K.B.,
Taylor, T.E., Molyneux, M.E., and Kain, K.C. (2010). Endothelium-based
biomarkers are associated with cerebral malaria in Malawian children: a retro-
spective case-control study. PLoS ONE 5, e15291.
Dellicour, S., Tatem, A.J., Guerra, C.A., Snow, R.W., and ter Kuile, F.O. (2010).
Quantifying the number of pregnancies at risk of malaria in 2007: a demo-
graphic study. PLoS Med. 7, e1000221.
Desai, M., ter Kuile, F.O., Nosten, F., McGready, R., Asamoa, K., Brabin, B.,
and Newman, R.D. (2007). Epidemiology and burden of malaria in pregnancy.
Lancet Infect. Dis. 7, 93–104.
Dorman, E.K., Shulman, C.E., Kingdom, J., Bulmer, J.N., Mwendwa, J., Peshu,
N., and Marsh, K. (2002). Impaired uteroplacental blood flow in pregnancies
complicated by falciparummalaria. Ultrasound Obstet. Gynecol. 19, 165–170.
Dunk, C., Shams,M., Nijjar, S., Rhaman, M., Qiu, Y., Bussolati, B., and Ahmed,
A. (2000). Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to
promote growth and migration during placental development. Am. J. Pathol.
156, 2185–2199.
Geva, E., Ginzinger, D.G., Zaloudek, C.J., Moore, D.H., Byrne, A., and Jaffe,
R.B. (2002). Human placental vascular development: vasculogenic and angio-
genic (branching and nonbranching) transformation is regulated by vascular
endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J. Clin.
Endocrinol. Metab. 87, 4213–4224.
Ghosh, G., Breborowicz, A., Brazert, M., Maczkiewicz, M., Kobelski, M.,
Dubiel, M., and Gudmundsson, S. (2006). Evaluation of third trimester uterine
artery flow velocity indices in relationship to perinatal complications. J. Matern.
Fetal Neonatal Med. 19, 551–555.Cell Host &Girardi, G., Yarilin, D., Thurman, J.M., Holers, V.M., and Salmon, J.E. (2006).
Complement activation induces dysregulation of angiogenic factors and
causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165–2175.
Gougos, A., St Jacques, S., Greaves, A., O’Connell, P.J., d’Apice, A.J.,
Bu¨hring, H.J., Bernabeu, C., van Mourik, J.A., and Letarte, M. (1992).
Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein
of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int. Immunol. 4,
83–92.
Guo, R.F., and Ward, P.A. (2005). Role of C5a in inflammatory responses.
Annu. Rev. Immunol. 23, 821–852.
Guyatt, H.L., and Snow, R.W. (2001). Malaria in pregnancy as an indirect cause
of infant mortality in sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg. 95,
569–576.
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. (1998). Flt-1
lacking the tyrosine kinase domain is sufficient for normal development and
angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95, 9349–9354.
Huber-Lang, M., Sarma, J.V., Zetoune, F.S., Rittirsch, D., Neff, T.A., McGuire,
S.R., Lambris, J.D., Warner, R.L., Flierl, M.A., Hoesel, L.M., et al. (2006).
Generation of C5a in the absence of C3: a new complement activation
pathway. Nat. Med. 12, 682–687.
Ismail, M.R., Ordi, J., Menendez, C., Ventura, P.J., Aponte, J.J., Kahigwa, E.,
Hirt, R., Cardesa, A., and Alonso, P.L. (2000). Placental pathology in malaria:
a histological, immunohistochemical, and quantitative study. Hum. Pathol.
31, 85–93.
Jeansson, M., Gawlik, A., Anderson, G., Li, C., Kerjaschki, D., Henkelman, M.,
and Quaggin, S.E. (2011). Angiopoietin-1 is essential in mouse vasculature
during development and in response to injury. J. Clin. Invest. 121, 2278–2289.
Kaufmann, P., Black, S., and Huppertz, B. (2003). Endovascular trophoblast
invasion: implications for the pathogenesis of intrauterine growth retardation
and preeclampsia. Biol. Reprod. 69, 1–7.
Landis, S.H., Ananth, C.V., Lokomba, V., Hartmann, K.E., Thorp, J.M., Jr.,
Horton, A., Atibu, J., Ryder, R.W., Tshefu, A., and Meshnick, S.R. (2009).
Ultrasound-derived fetal size nomogram for a sub-Saharan African population:
a longitudinal study. Ultrasound Obstet. Gynecol. 34, 379–386.
Langer, H.F., Chung, K.J., Orlova, V.V., Choi, E.Y., Kaul, S., Kruhlak, M.J.,
Alatsatianos, M., DeAngelis, R.A., Roche, P.A., Magotti, P., et al. (2010).
Complement-mediated inhibition of neovascularization reveals a point of
convergence between innate immunity and angiogenesis. Blood 116, 4395–
4403.
Leke, R., Cadigan, T.J., Mbu, R., Leke, R.I.J., Fogako, J., Megnikou, R.,
Metenou, S., Sama, G., Zhou, Y., and Taylor, D.W. (2002). Plasmodium falcipa-
rum Infection in Pregnant CameroonianWomen: An Assessment of Changes in
the Placenta of Low BirthWeight Infants. Journal of the Cameroon Academy of
Sciences 2, 203–212.
Levine, R.J., Lam, C., Qian, C., Yu, K.F., Maynard, S.E., Sachs, B.P., Sibai,
B.M., Epstein, F.H., Romero, R., Thadhani, R., and Karumanchi, S.A.; CPEP
Study Group. (2006a). Soluble endoglin and other circulating antiangiogenic
factors in preeclampsia. N. Engl. J. Med. 355, 992–1005.
Levine, R.J., Qian, C., Maynard, S.E., Yu, K.F., Epstein, F.H., and Karumanchi,
S.A. (2006b). Serum sFlt1 concentration during preeclampsia and mid
trimester blood pressure in healthy nulliparous women. Am. J. Obstet.
Gynecol. 194, 1034–1041.
Lynch, A.M., and Salmon, J.E. (2010). Dysregulated complement activation as
a common pathway of injury in preeclampsia and other pregnancy complica-
tions. Placenta 31, 561–567.
Maynard, S.E., Min, J.Y., Merchan, J., Lim, K.H., Li, J., Mondal, S., Libermann,
T.A., Morgan, J.P., Sellke, F.W., Stillman, I.E., et al. (2003). Excess placental
soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial
dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest.
111, 649–658.
McKeeman, G.C., Ardill, J.E., Caldwell, C.M., Hunter, A.J., and McClure, N.
(2004). Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is
increased throughout gestation in patients who have preeclampsia develop.
Am. J. Obstet. Gynecol. 191, 1240–1246.Microbe 13, 215–226, February 13, 2013 ª2013 Elsevier Inc. 225
Cell Host & Microbe
Placental Malaria, Complement, and AngiogenesisMiquerol, L., Langille, B.L., and Nagy, A. (2000). Embryonic development is
disrupted by modest increases in vascular endothelial growth factor gene
expression. Development 127, 3941–3946.
Muehlenbachs, A., Fried, M., Lachowitzer, J., Mutabingwa, T.K., and Duffy,
P.E. (2007). Genome-wide expression analysis of placental malaria reveals
features of lymphoid neogenesis during chronic infection. J. Immunol. 179,
557–565.
Muehlenbachs, A., Fried, M., Lachowitzer, J., Mutabingwa, T.K., and Duffy,
P.E. (2008). Natural selection of FLT1 alleles and their association with malaria
resistance in utero. Proc. Natl. Acad. Sci. USA 105, 14488–14491.
Neres, R., Marinho, C.R., Gonc¸alves, L.A., Catarino, M.B., and Penha-
Gonc¸alves, C. (2008). Pregnancy outcome and placenta pathology in
Plasmodium berghei ANKA infected mice reproduce the pathogenesis of
severe malaria in pregnant women. PLoS ONE 3, e1608.
Pries, A.R., and Secomb, T.W. (2003). Rheology of the microcirculation. Clin.
Hemorheol. Microcirc. 29, 143–148.
Rennie, M.Y., Detmar, J., Whiteley, K.J., Yang, J., Jurisicova, A., Adamson,
S.L., and Sled, J.G. (2011). Vessel tortuousity and reduced vascularization in
the fetoplacental arterial tree after maternal exposure to polycyclic aromatic
hydrocarbons. Am. J. Physiol. Heart Circ. Physiol. 300, H675–H684.
Riedemann, N.C., Guo, R.F., Neff, T.A., Laudes, I.J., Keller, K.A., Sarma, V.J.,
Markiewski, M.M., Mastellos, D., Strey, C.W., Pierson, C.L., et al. (2002).
Increased C5a receptor expression in sepsis. J. Clin. Invest. 110, 101–108.
Rogerson, S.J., Pollina, E., Getachew, A., Tadesse, E., Lema, V.M., and
Molyneux, M.E. (2003). Placental monocyte infiltrates in response to
Plasmodium falciparum malaria infection and their association with adverse
pregnancy outcomes. Am. J. Trop. Med. Hyg. 68, 115–119.
Rogerson, S.J., Mwapasa, V., and Meshnick, S.R. (2007). Malaria in preg-
nancy: linking immunity and pathogenesis to prevention. Am. J. Trop. Med.
Hyg. 77(6, Suppl), 14–22.
Sapin, V., Blanchon, L., Serre, A.F., Le´mery, D., Dastugue, B., and Ward, S.J.
(2001). Use of transgenic mice model for understanding the placentation:
towards clinical applications in human obstetrical pathologies? Transgenic
Res. 10, 377–398.
Sato, T.N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y.,
Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and Qin, Y.
(1995). Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood
vessel formation. Nature 376, 70–74.
Silver, K.L., Higgins, S.J., McDonald, C.R., and Kain, K.C. (2010a).
Complement driven innate immune response to malaria: fuelling severe malar-
ial diseases. Cell. Microbiol. 12, 1036–1045.226 Cell Host & Microbe 13, 215–226, February 13, 2013 ª2013 ElseSilver, K.L., Zhong, K., Leke, R.G., Taylor, D.W., and Kain, K.C. (2010b).
Dysregulation of angiopoietins is associated with placental malaria and low
birth weight. PLoS ONE 5, e9481.
Silver, K.L., Conroy, A.L., Leke, R.G., Leke, R.J., Gwanmesia, P., Molyneux,
M.E., Taylor, D.W., Rogerson, S.J., and Kain, K.C. (2011). Circulating soluble
endoglin levels in pregnant women in Cameroon and Malawi—associations
with placental malaria and fetal growth restriction. PLoS ONE 6, e24985.
Soto, E., Romero, R., Richani, K., Espinoza, J., Chaiworapongsa, T., Nien, J.K.,
Edwin, S.S., Kim, Y.M., Hong, J.S., Goncalves, L.F., et al. (2010). Preeclampsia
and pregnancies with small-for-gestational age neonates have different
profiles of complement split products. J. Matern. Fetal Neonatal Med. 23,
646–657.
Steketee, R.W., Nahlen, B.L., Parise, M.E., and Menendez, C. (2001). The
burden of malaria in pregnancy in malaria-endemic areas. Am. J. Trop. Med.
Hyg. 64(1-2, Suppl), 28–35.
Umbers, A.J., Aitken, E.H., and Rogerson, S.J. (2011a). Malaria in pregnancy:
small babies, big problem. Trends Parasitol. 27, 168–175.
Umbers, A.J., Boeuf, P., Clapham, C., Stanisic, D.I., Baiwog, F., Mueller, I.,
Siba, P., King, C.L., Beeson, J.G., Glazier, J., and Rogerson, S.J. (2011b).
Placental malaria-associated inflammation disturbs the insulin-like growth
factor axis of fetal growth regulation. J. Infect. Dis. 203, 561–569.
Venkatesha, S., Toporsian, M., Lam, C., Hanai, J., Mammoto, T., Kim, Y.M.,
Bdolah, Y., Lim, K.H., Yuan, H.T., Libermann, T.A., et al. (2006). Soluble endo-
glin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642–649.
Ward, P.A. (2004). The dark side of C5a in sepsis. Nat. Rev. Immunol. 4,
133–142.
Ward, P.A. (2009). Functions of C5a receptors. J. Mol. Med. 87, 375–378.
Watson, E.D., and Cross, J.C. (2005). Development of structures and transport
functions in the mouse placenta. Physiology (Bethesda) 20, 180–193.
Wort, U.U., Hastings, I., Mutabingwa, T.K., and Brabin, B.J. (2006). The impact
of endemic and epidemic malaria on the risk of stillbirth in two areas of
Tanzania with different malaria transmission patterns. Malar. J. 5, 89.
Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., and
Holash, J. (2000). Vascular-specific growth factors and blood vessel forma-
tion. Nature 407, 242–248.
Yang, J., Yu, L.X., Rennie, M.Y., Sled, J.G., and Henkelman, R.M. (2010).
Comparative structural and hemodynamic analysis of vascular trees. Am. J.
Physiol. Heart Circ. Physiol. 298, H1249–H1259.
Yatich, N.J., Funkhouser, E., Ehiri, J.E., Agbenyega, T., Stiles, J.K., Rayner,
J.C., Turpin, A., Ellis, W.O., Jiang, Y., Williams, J.H., et al. (2010). Malaria,
intestinal helminths and other risk factors for stillbirth in Ghana. Infect. Dis.
Obstet. Gynecol. 2010, 350763.vier Inc.
